Tracking and Exploring the Source of Viral REbound
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Genetic Cartography
研究概览
简要总结
Phylogenic analysis of viruses hosted in marker positive reservoir cells including CD32a+ CD4 T lymphocytes and rebounding viruses after treatment interruption
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Age>18year old
- •Nadir CD4>200/mm3
- •CD4/CD8 ratio> 0.5
- •Continuous antiretroviral therapy for more than 2 years
- •Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) <50 copies/ml in the last 2 years
- •Viral Load (VL)<20copies at inclusion
- •Patients who are willing to participate and who understand the trial (particularly, the obligation to have protected intercourse during the study).
- •Informed consent
- •Short half-life treatment
- •Health insurance
- •A subset of CD4 (T4cells) express CD32a.
排除标准
- •- Acquired Immune Deficiency Syndom (AIDS)
- •Pregnancy
- •Human immunodeficiency virus (HIV)-2 co infection
- •Thrombopenia
- •Neurological events during primary infection
- •Hepatitis B + (HBV+)
- •Hepatitis C + (HCV+)
- •Cancer during the last 5 years.
- •Life expectancy < 12 months
- •Autoimmunity
- •Acute infectious disease in the last 60 days.
- •Hemoglobin<7g/dl
- •Glomerular filtration < 60ml/min
- •Refusing protected intercourse
- •Risk of HIV transmission
- •Psychiatric disorders.
- •Alcool and drug abuse
- •Involvement in another clinical trial evaluating a therapeutic.
- •Being under tutorship
- •Being deprived of liberty
研究组 & 干预措施
Antiretroviral therapy
Stopping antiretroviral therapy
干预措施: no drug (Other)
结局指标
主要结局
Genetic Cartography
时间窗: Week 12
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 1
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 2
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 3
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 4
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 5
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 6
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 8
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
Genetic Cartography
时间窗: Week 10
Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml
次要结局
未报告次要终点